Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Clinical Study on The Long-term Safety and Efficacy of Multiple Treatments With Recombinant Botulinum Toxin Type A (YY001) for Injection in Adult Upper Limb Spasticity (REHAB-2)

NCT07478822 is registered in ClinicalTrials.gov with Chongqing Claruvis Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07478822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07478822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Clinical Study on The Long-term Safety and Efficacy of Multiple Treatments With Recombinant Botulinum Toxin Type A (YY001) for Injection in Adult Upper Limb Spasticity (REHAB-2)
Lead sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
March 27, 2026
Completion date
June 1, 2027
Enrollment
300 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

upper limb spasticity